Table 2.
Association of baseline kidney functional MRI measurements with change in eGFR over time
| Kidney Functional MRI Biomarker | Model 1 | Model 2 | Model 3 | |||
|---|---|---|---|---|---|---|
| β (95% CI)a | P Value | β (95% CI)a | P Value | β (95% CI)a | P Value | |
| Cortical ADC | 1.2 (−0.002 to 2.4) | 0.05 | 1.3 (0.1 to 2.5) | 0.04 | 1.0 (−0.1 to 2.2) | 0.08 |
| Cortical R2* | 0.6 (−0.6 to 1.7) | 0.32 | 0.6 (−0.6 to 1.7) | 0.33 | 0.5 (−0.6 to 1.5) | 0.40 |
Model 1 is unadjusted. Model 2 is adjusted for age, sex, race, diabetes status, treatment group (active treatment versus placebo), study center, baseline hemoglobin, baseline log-transformed UACR, and baseline eGFR. Model 3 is model 2 and further adjusts for the interaction of natural log-transformed UACR×time. MRI, magnetic resonance imaging; 95% CI, 95% confidence interval; ADC, apparent diffusion coefficient; R2*, relaxation rate; UACR, urine albumin-to-creatinine ratio.
The β estimate is the difference in annual eGFR slope (ml/min per 1.73 m2 per year) per 1 SD increase in the MRI biomarker of interest from the respective MRI biomarker×time interaction term. P values are from the interaction term of each respective MRI biomarker×time. Cortical ADC and R2* are reported in ×10−3 mm2/s and s−1, respectively. Time is measured in years.